...and diabetes patients
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific claims superior two-year results for Taxus compared to Cypher and bare-metal stents in a population of patients with diabetes, based on 708-patient registry data reported at the AHA Scientific Sessions Nov. 14. In the European T-Search/Research study, the target vessel revascularization rate was 9.7% for Taxus compared with 15.3% for Cypher and 19.5% for bare-metal stents. MACE (major adverse cardiac event) rates were 21.2% with Taxus, 28.9% with Cypher and 29.7% with bare-metal stents. Data from 1,182 diabetic patients in another Boston Scientific-sponsored registry reported earlier this year showed no statistically significant difference between the two drug-eluting products (1"The Gray Sheet" March 20, 2006, p. 4). Diabetics make up 25% of patients receiving coronary interventional procedures in the U.S., Boston Scientific says...
You may also be interested in...
Drug-Eluting Stent Wars Reach Standoff In Diabetic Patients
The largest comparison to date of paclitaxel-versus sirolimus-eluting stents in diabetic patients failed to show a statistically significant difference in outcomes between the two devices, according to findings unveiled March 12 at the American College of Cardiology's annual meeting in Atlanta
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.